ClinicalTrials.gg
CompletedNCT02700659Updated Mar 4, 2020

The Cxbladder Monitoring Study

An observational study in Urothelial Carcinoma, sponsored by Pacific Edge Limited. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Pacific Edge Limited · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
803
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 141 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Enrollment
8th of 25
803 · median 389
Started
2013
with 3 others
Observational
25 of 361
9 open now
Registered
79th of 361
by date

Among the 361 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 8th largest by enrollment of the 25 observational ones that give a count, is one of 4 that started in 2013, is one of 25 observational ones, and was the 79th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 361 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated according to standard practice and are undergoing routine investigative cystoscopy.

The gold standard for determination of clinical truth is cystoscopy, plus any follow up investigations relating to the current visit.

03

Conditions studied

  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects were recruited from community and referral centres. Patients were under surveillance for recurring urothelial carcinoma monitoring, and undergoing all standard of care, including investigative cystoscopy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed positive diagnosis for primary or recurrent urinary tract UC over the past 2 years.
  • Patient is undergoing investigative cystoscopies for the monitoring of recurrence of UC at intervals prescribed by a clinical practitioner
  • Patient is 18 years of age or older.

Exclusion criteria

Exclusion Criteria:

  • Prior genitourinary manipulation (cystoscopy / catheterisation / dilation) in the 14 days before urine collection, current urinary tract infection, current or known history of urinary tract inflammatory disorder, recent history of glomerulonephritis, nephrosis or other renal inflammatory disorders, recent history of pyelonephritis
  • Patient has undergone total bladder cystectomy as treatment for bladder UC
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
803 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • UC monitoring patients

    Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.

    Other: Cxbladder

Interventions

  • OtherCxbladder

    Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with bladder cancer who are correctly identified as having cancer (true positives) and no cancer (true negatives) by the Cxbladder test.

    The Cxbladder test results will be compared to that of cystoscopy, which is the gold standard method for diagnosing urothelial cancer; the true positive and true negative rates will be measured, along with the false positive and false negative rates of the test. The results will be reported as sensitivity and specificity of the Cxbladder test for detecting urothelial cancer in patients with recurrent disease.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

  2. Probability that patients identified as having cancer and no cancer by the Cxbladder test truly have cancer (positive predictive value; PPV), and truly have no cancer (negative predictive value; NPV) respectively.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

Secondary outcomes

  1. Comparison of the Cxbladder test's sensitivity, specificity, PPV and NPV with that of Cytology.

    Performance characteristics (sensitivity, specificity, PPV and NPV) of the Cxbladder test for detecting recurring urothelial cancer will be compared to urine cytology, in addition to the gold standard test (cystoscopy). All comparator tests will be carried out on the same voided urine sample used for Cxbladder tests.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

  2. Comparison of the Cxbladder test's sensitivity, specificity, PPV and NPV with that of NMP22 ELISA Assay.

    Performance characteristics (sensitivity, specificity, PPV and NPV) of the Cxbladder test for detecting recurring urothelial cancer will be compared to NMP22 ELISA, in addition to the gold standard test (cystoscopy). All comparator tests will be carried out on the same voided urine sample used for Cxbladder tests.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

  3. Comparison of the Cxbladder test's sensitivity, specificity, PPV and NPV with that of NMP22 BladderChek Assay.

    Performance characteristics (sensitivity, specificity, PPV and NPV) of the Cxbladder test for detecting recurring urothelial cancer will be compared to NMP22 BladderChek, in addition to the gold standard test (cystoscopy). All comparator tests will be carried out on the same voided urine sample used for Cxbladder tests.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

07

Study locations

11 sites
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
  • Urology Center of Grove Hill, One Lake Street
    New Britain, Connecticut 06052, United States
  • Florida Urology Associates
    Orlando, Florida 32803, United States
  • Idaho Urologic Institute
    Meridian, Idaho 83642, United States
  • Delaware Valley Urology, LLC
    New Jersey, New Jersey 08054, United States
  • Premier Medical Group of the Hudson Valley
    Kingston, New York 12401, United States
  • Weill Cornell Medical College, Department of Urology
    New York, New York 10065, United States
  • Premier Medical Group of the Hudson Valley
    New York, New York 12061, United States
  • Premier Medical Group of the Hudson Valley
    Newburgh, New York 12550, United States
  • Penn State Hershey Medical Center and College of Medicine
    Hershey, Pennsylvania 17033, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
08

References and documents

Publications

  • Lough T, Luo Q, O'Sullivan P, Chemasle C, Stotzer M, Suttie J, Darling D. Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician-Patient Real-World Clinical Data Analysis. Oncol Ther. 2018 Jun;6(1):73-85. doi: 10.1007/s40487-018-0059-5. Epub 2018 Apr 19. PubMed 32700139 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Sep 2016, 43 months.

Of 61 observational studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 89. This study's 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2016
First posted
Mar 7, 2016
StartActual
Feb 4, 2013
Primary completionActual
Sep 23, 2016
CompletionActual
Sep 23, 2016
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02700659
Lead sponsor
Pacific Edge Limited
Responsible party
Sponsor
First posted
Mar 7, 2016
Start date
Feb 4, 2013
Primary completion
Sep 23, 2016
Completion
Sep 23, 2016
Last update
Mar 4, 2020

Study contacts

Paul J O'Sullivan, PhD
study chair · Pacific Edge Limited

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion